General Counsel — John Brottem: The General Counsel is resigning to pursue other opportunities without any dispute, representing a standard executive departure.

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This Current on Form 8-K contains forward-looking stat…

Entry into a Material Definitive Agreement. On June 14, 2026, Outset Medical, Inc., (the “Company”) entered into the Refresh Amendment (the “Amendment”) to the Purchasing Agreement with HCA Management Services, L.P. (“HCA”), dated May 1, 2020, as amended (collectively, the “Agreement”). Under the terms of the Amendment, the parties have agreed, among other things, for HCA to refresh its existing fleet of Tablo Hemodialysis Systems by purchasing new Tablo Hemodialysis Systems commencing in 202…

Executive Vice President, R&D, Operations and Service — Marc Nash: Mr. Nash is leaving to pursue other professional opportunities.

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This report and the exhibit attached hereto contain f…

Director — Andrea Saia: Ms. Saia resigned from the Board, and Ms. Prange was appointed as a new director.

Result of Operations and Financial Condition. On January 12, 2026, Outset Medical, Inc. (the “Company”) issued a press release announcing, among other items, expected revenue for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. Certain financial information contained in Exhibit 99.1 is preliminary, unaudited and subject to change or adjustment in connection with the completion of the Company’s quarter and year-end c…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This report and the exhibit attached hereto contain f…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This report and the exhibit attached hereto contain f…

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer — Renee Gaeta: The company appointed a new Chief Financial Officer from an external hire.

Director — Dale E. Jones: Mr. Dale E. Jones resigned from the Board of Directors, and Kevin O'Boyle was appointed as a new director.

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Material Modification to Rights of Security Holders. The information set forth in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing As previously disclosed, on September 23, 2024, Outset Medical, Inc. (the “Company”) received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued…

Result of Operations and Financial Condition. On February 19, 2025, Outset Medial, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and year ended December 31, 2024, as well as a guidance for 2025 revenue and non-GAAP gross margin. On the same date, the Company will hold its fourth quarter and full year 2024 earnings conference call. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The…

Termination of a Material Definitive Agreement. As previously disclosed, on January 3, 2025, the Company entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Holdings IV, LP as the administrative agent (“Agent”) and initial lender. On the Closing Date, the Company borrowed the initial term loan in the principal amount of $100.0 million, and used the proceeds of such loan, together with cash on hand, to repay in full all amounts due under its two existin…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On the Closing Date, the Company borrowed the initial term loan in the principal amount of $100.0 million and issued to Perceptive Credit Holdings IV, LP as the initial lender a warrant to purchase 5,625,000 of shares of the Company’s common stock, par value $0.001 (the “Common Stock”) (the “Closing Date Warrant”), at an exercise price equal to $0.80. If the Company draws the del…

Entry into a Material Definitive Agreement. As previously disclosed, on January 3, 2025, Outset Medical, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with various investors, including certain members of management and certain members of the Company’s Board of Directors for the issuance and sale by the Company of an aggregate of 863,340 shares of Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series A…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This report and the exhibit attached hereto contain forward-looking statem…

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. Private Placement On January 3, 2025, Outset Medical, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with various investors, including certain members of management and certain members of the Company’s Board of Directors (the “Investors”) for the issuance and sale by the Company of an aggregate of 863,340 shares of Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (th…

Result of Operations and Financial Condition. On January 6, 2025, the Company issued a press release announcing, among other items, the signing of the Securities Purchase Agreements, entrance into the Credit Agreement, and expected revenue for the fourth quarter and fiscal year ended December 31, 2024. A copy of the Company’s press release is furnished herewith as Exhibit 99.1. Certain financial information contained in Exhibit 99.1 is preliminary, unaudited and subject to change or adjustmen…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This report and the exhibit at…